West Pharmaceutical Services (WST) reported a 5.2% stock increase following strong 2025 results, with sales reaching US$3.07 billion and net income at US$493.7 million. The company issued encouraging 2026 guidance, expecting first-quarter net sales of US$770-$790 million and full-year sales of US$3.22-$3.28 billion, emphasizing organic net sales growth as a key driver. This updated outlook helps investors understand the impact of underlying demand and product mix on the company’s financial performance.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook
West Pharmaceutical Services (WST) reported a 5.2% stock increase following strong 2025 results, with sales reaching US$3.07 billion and net income at US$493.7 million. The company issued encouraging 2026 guidance, expecting first-quarter net sales of US$770-$790 million and full-year sales of US$3.22-$3.28 billion, emphasizing organic net sales growth as a key driver. This updated outlook helps investors understand the impact of underlying demand and product mix on the company’s financial performance.